Clinical trials including an update on the Helsinki Heart Study

Area of Science:

• Cardiology
• Preventive Medicine
• Lipid Metabolism

Background:

• Elevated blood cholesterol is a major risk factor for coronary heart disease (CHD), including myocardial infarction (MI) and sudden death.
• Multiple clinical trials have established the benefit of lowering cholesterol through various interventions.
• Dietary and pharmacological approaches have demonstrated efficacy in reducing CHD events.

Purpose of the Study:

• To review the evidence supporting cholesterol reduction for preventing coronary heart disease.
• To summarize findings from key clinical trials investigating lipid-lowering interventions.
• To highlight the relationship between cholesterol levels and CHD incidence.

Main Methods:

• Review of published clinical trials and epidemiological studies.
• Analysis of data from interventions including diet, niacin, clofibrate, cholestyramine, and gemfibrozil.
• Examination of primary and secondary end points related to CHD events and mortality.

Main Results:

• Dietary interventions achieved 10-15% cholesterol reduction, correlating with 20-50% CHD reduction.
• Niacin and clofibrate showed significant MI reduction, though one trial noted unexplained increased mortality with clofibrate.
• Cholestyramine and gemfibrozil demonstrated significant reductions in major CHD end points, with gemfibrozil also increasing HDL cholesterol.

Conclusions:

• Lowering blood cholesterol is a proven strategy for reducing myocardial infarction and sudden death.
• Different lipid-lowering agents show varying effects on CHD outcomes and lipid profiles.
• Further research is needed to understand unexplained findings, such as increased mortality in specific trials.